Akums Drugs and Pharmaceuticals reported Q3FY26 standalone net profit of ₹281.14 million, down 32% from ₹411.68 million in Q3FY25, despite 9.2% revenue growth to ₹3,686.06 million. The company faced exceptional charges of ₹38.08 million related to new Labour Code compliance. Nine-month performance showed similar trends with revenue up 2.8% to ₹10,103.64 million but net profit declining 27.7% to ₹964.43 million.
Akums Drugs Q3FY26 Profit Declines 32% to ₹281.14 Million Despite Revenue Growth
